MedTrace Logo

Edaravone Dexborneol for Treatment of Hypertensive Intracerebral Hemorrhage

NCT04714177 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 390

Last updated 2021-01-19

No results posted yet for this study

Summary

pending

Conditions

  • Intracerebral Hemorrhage

Interventions

DRUG

Edaravone Dexborneol

Edaravone Dexborneol 37.5 mg, containing Edaravone 30 mg and Dexborneol 7.5 mg, Edaravone Dexborneol 37.5 mg BID, 14 days, addition to standard of care of Intracerebral Hemorrhage

DRUG

Placebo

Edaravone Dexborneol matching injection, addition to standard of care of Intracerebral Hemorrhage

Sponsors & Collaborators

  • Jiangsu Simcere Pharmaceutical Co., Ltd.

    collaborator INDUSTRY

  • First Affiliated Hospital, Sun Yat-Sen University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-01
Primary Completion
2023-03-01
Completion
2023-09-01

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04714177 on ClinicalTrials.gov